Cincinnati Offers Outpatient CAR-T Cancer Therapy
Patients with follicular lymphoma can now receive this cellular treatment as an outpatient and recover at home.
Updated on Oct. 26, 2026 in Cancer
The UC Cancer Center recently began offering CAR-T cell therapy on an outpatient basis, allowing patients to recover at home rather than in a hospital. Tamara Schwarting became the first patient to undergo this procedure at the facility in 2026.
Why it matters
Transitioning CAR-T therapy to an outpatient model aims to improve quality of life for cancer patients by providing a more comfortable home recovery environment. The approach supports patient convenience while maintaining necessary medical oversight.
In a 2026 procedure at the UC Cancer Center, doctors administered CAR-T cell therapy in an outpatient setting, a change from standard inpatient protocols. The clinical feasibility of this model is currently being evaluated for broader application.
The players
UC Cancer Center
An academic medical facility in Cincinnati providing specialized cancer care and research.
Tamara Schwarting
The first patient to receive CAR-T cell therapy as an outpatient at the UC Cancer Center.
The details
CAR-T cell therapy functions by extracting a patient’s T-cells, which are then genetically modified in a laboratory to better recognize and target cancer cells. Once reinfused into the patient, the cells work to identify and eliminate the cancer. During this outpatient process, the reinfusion itself takes less than 10 minutes, and patients receive specialized training on managing potential side effects at home with a 24-hour nurse hotline.
Timeline
May 2021: Tamara Schwarting was diagnosed with follicular lymphoma.
2026: Schwarting received outpatient CAR-T cell therapy.
Health Landscape
The shift toward outpatient delivery marks an evolution in how complex cellular immunotherapies are provided to patients with lymphoma. This approach seeks to align advanced cancer treatments with modern trends favoring recovery in home environments.
For patients considering CAR-T cell therapy, the transition to outpatient care may offer a significant change in comfort and recovery logistics. It is worth discussing with your oncology team whether an outpatient setting is available and safe for your specific health needs.
The takeaway
Outpatient CAR-T therapy represents a shift in how cancer patients recover from genetically modified cell treatments. If you are a candidate for cellular immunotherapy, ask your physician about the possibility of outpatient management and what support systems, such as 24-hour hotlines, are in place.
Further reading
For more information on current treatment standards and local options, see Cancer.
Source note: This article includes information reported by WLWT5.
